Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts

@inproceedings{Cueva2013Combined5A,
  title={Combined 5-FU and ChoKα Inhibitors as a New Alternative Therapy of Colorectal Cancer: Evidence in Human Tumor-Derived Cell Lines and Mouse Xenografts},
  author={Ana de la Cueva and Ana Ram{\'i}rez de Molina and N{\'e}stor {\'A}lvarez-Ayerza and Ma Angeles Ramos and Arancha Cebri{\'a}n and Teresa G{\'o}mez del Pulgar and Juan Carlos Lacal},
  booktitle={PloS one},
  year={2013}
}
BACKGROUND Colorectal cancer (CRC) is the third major cause of cancer related deaths in the world. 5-fluorouracil (5-FU) is widely used for the treatment of colorectal cancer but as a single-agent renders low response rates. Choline kinase alpha (ChoKα), an enzyme that plays a role in cell proliferation and transformation, has been reported overexpressed in many different tumors, including colorectal tumors. ChoKα inhibitors have recently entered clinical trials as a novel antitumor strategy… CONTINUE READING
Highly Cited
This paper has 28 citations. REVIEW CITATIONS
15 Citations
55 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Similar Papers

Loading similar papers…